The American Depositary Shares ("ADS") of the United Kingdom-based biotech Compass Pathways plc (CMPS) are soaring today, after management announced its psychedelic drug candidate COMP006 had met the ...

Phase 3 clinical trial data has been a success. COMP360 is the first traditional psychedelic to consistently deliver a highly statistically significant outcome. Results included maintaining a ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the British biotech’s share price up 30% and teeing up talks about filing for ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Compass Pathways on ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. A psychedelic medicine for hard-to-treat depression ...

Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical Officer Guy Goodwin. By providing 26 weeks’ worth of such data instead of the ...

A psychedelic medicine for hard-to-treat depression could be under approval review before the end of this year, now that its developer has scored positive data from another large clinical trial.

In their closing arguments, attorneys for the two companies addressed claims of collusion, harm to Compass and more. Now a judge will decide what happens next. The preliminary injunction hearing in ...

Compass, the nation’s largest residential real-estate brokerage, has a pitch for home buyers: Sign with us, and you’ll see homes nobody else can. The company maintains a growing inventory of “Private ...

Following a major update for the 2023 model year, the Jeep Compass carries over with minor changes for 2024. Jeep's in-betweener sits above the subcompact Renegade and below the Grand Cherokee within ...

Frankly, the Jeep Compass has failed to impress us. Sweeping updates applied for 2022 help slightly, but not much. The Compass slots between the diminutive Renegade and the compact Cherokee in Jeep's ...